Group 1 - Abbott reported quarterly earnings of 1.21pershare,exceedingtheZacksConsensusEstimateof1.20 per share, and up from 1.14pershareayearago,representinganearningssurpriseof0.8310.64 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 0.71% and increasing from 10.14billionyear−over−year[1]−Overthelastfourquarters,AbbotthassurpassedconsensusEPSestimatesthreetimesandtoppedconsensusrevenueestimatesfourtimes[1]Group2−Thestock′simmediatepricemovementwilldependonmanagement′scommentaryduringtheearningscall,withAbbottshareshavinggainedabout5.41.34 on revenues of 10.87billion,andforthecurrentfiscalyear,itis4.66 on revenues of $41.77 billion [4] - The Medical - Products industry, to which Abbott belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook for the sector [5]